Literature DB >> 9512357

Calcium currents and transients of native and heterologously expressed mutant skeletal muscle DHP receptor alpha1 subunits (R528H)

K Jurkat-Rott1, U Uetz, U Pika-Hartlaub, J Powell, B Fontaine, W Melzer, F Lehmann-Horn.   

Abstract

Rabbit cDNA of the alpha1 subunit of the skeletal muscle dihydropyridine (DHP) receptor was functionally expressed in a muscular dysgenesis mouse (mdg) cell line, GLT. L-type calcium currents and transients were recorded for the wild type and a mutant alpha1 subunit carrying an R528H substitution in the supposed voltage sensor of the second channel domain that is linked to a human disease, hypokalemic periodic paralysis. L-type channels expressed in GLT myotubes exhibited currents similar to those described for primary cultured mdg cells injected with rabbit wild type cDNA, indicating this system to be useful for functional studies of heterologous DHP receptors. Voltage dependence and kinetics of activation and inactivation of L-type calcium currents from mutant and wild type channels did not differ significantly. Intracellular calcium release activation measured by fura-2 microfluorimetry was not grossly altered by the mutation either. Analogous measurements on myotubes of three human R528H carriers revealed calcium transients comparable to controls while the voltage dependence of both activation and inactivation of the L-type current showed a shift to more negative potentials of approximately 6 mV. Similar effects on the voltage dependence of the fast T-type current and changes in the expression level of the third-type calcium current point to factors not primarily associated with the mutation perhaps participating in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512357     DOI: 10.1016/s0014-5793(98)00090-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

1.  Kinetics of inactivation and restoration from inactivation of the L-type calcium current in human myotubes.

Authors:  C Harasztosi; I Sipos; L Kovacs; W Melzer
Journal:  J Physiol       Date:  1999-04-01       Impact factor: 5.182

Review 2.  Periodic paralysis: understanding channelopathies.

Authors:  Frank Lehmann-Horn; Karin Jurkat-Rott; Reinhardt Rüdel
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

Review 3.  Skeletal muscle sodium current is reduced in hypokalemic periodic paralysis.

Authors:  R L Ruff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  Channelopathies.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

5.  Voltage-activated calcium signals in myotubes loaded with high concentrations of EGTA.

Authors:  R P Schuhmeier; B Dietze; D Ursu; F Lehmann-Horn; W Melzer
Journal:  Biophys J       Date:  2003-02       Impact factor: 4.033

6.  Functional interaction of CaV channel isoforms with ryanodine receptors studied in dysgenic myotubes.

Authors:  Ralph Peter Schuhmeier; Elodie Gouadon; Daniel Ursu; Nicole Kasielke; Bernhard E Flucher; Manfred Grabner; Werner Melzer
Journal:  Biophys J       Date:  2004-12-30       Impact factor: 4.033

Review 7.  Muscle channelopathies and critical points in functional and genetic studies.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 8.  Ion channels and ion transporters of the transverse tubular system of skeletal muscle.

Authors:  Karin Jurkat-Rott; Michael Fauler; Frank Lehmann-Horn
Journal:  J Muscle Res Cell Motil       Date:  2006-08-24       Impact factor: 2.698

9.  Gating of the HypoPP-1 mutations: I. Mutant-specific effects and cooperativity.

Authors:  Alexey Kuzmenkin; Chao Hang; Elza Kuzmenkina; Karin Jurkat-Rott
Journal:  Pflugers Arch       Date:  2007-02-27       Impact factor: 3.657

Review 10.  Voltage-sensor mutations in channelopathies of skeletal muscle.

Authors:  Stephen C Cannon
Journal:  J Physiol       Date:  2010-02-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.